Oral bisphosphonate use and risk of postmenopausal endometrial cancer

Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, Garnet L. Anderson, Jean Wactawski-Wende, Gloria Y F Ho, Mary Jo O'Sullivan, Rowan T. Chlebowski

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

Original languageEnglish (US)
Pages (from-to)1186-1190
Number of pages5
JournalJournal of Clinical Oncology
Volume33
Issue number10
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Newcomb, P. A., Passarelli, M. N., Phipps, A. I., Anderson, G. L., Wactawski-Wende, J., Ho, G. Y. F., O'Sullivan, M. J., & Chlebowski, R. T. (2015). Oral bisphosphonate use and risk of postmenopausal endometrial cancer. Journal of Clinical Oncology, 33(10), 1186-1190. https://doi.org/10.1200/JCO.2014.58.6842